FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

	Check this box if no longer subject to
\Box	Section 16. Form 4 or Form 5
\cup	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Pellini Michael J (Last) (First) (Middle)				S. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT] 3. Date of Earliest Transaction (Month/Day/Year)										ck all applic Directo	able)	g Pers	10% Ov Other (s below)	vner	
C/O ADAPTIVE BIOTECHNOLOGIES CORP.			03/0	01/20)21														
SUITE 200					4 If	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable													
(Street) SEATTL	E W	Ά	98102			03/03/2021 Line) X Form fill								led by One Reporting Person led by More than One Reporting					
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			2. Transa Date (Month/D		er) if	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		Disposed	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			5. Amou Securitie Beneficia Owned F Reported	s ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				(111511.4)		
Common Stock 03				03/01	/2021		М		20,00	20,000 A		\$6.55	21,504			D			
Common Stock 03.				03/01	/2021		S		20,00	20,000 D \$		\$57.8(1)	1,504			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, T	ransac Code (In	ction nstr.			6. Date Exercisal: Expiration Date (Month/Day/Year)		е	of Securities		curity	3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nu of	nount mber ares					
Stock Option (Right to Buy)	\$6.55	03/01/2021			М			20,000	(2)		02/07/2028	Commo Stock	n 20),000	\$0.00	55,000)	D	

Explanation of Responses:

- 1. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$57.75 to 58.19, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- 2. The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Remarks:

/s/ Michael Pellini by Eric L.

<u>Billings, attorney-in-fact</u>

** Signature of Reporting Person

03/10/2021

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.